Ron Renaud, biotech’s serial CEO, is ready for a new assignment — and maybe another deal?

Taking stock of the drug industry, from the lab to the medicine chest

October 3, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Courtesy Patrick O'Connor STAT+ | Ron Renaud, biotech's serial CEO, is ready for a new assignment — and maybe another deal? At age 55, Renaud, now with Kailera Therapeutics, could be spending more time with his Cape Cod fishing buddies. But he can't quit biotech. By Adam Feuerstein STAT+ | ResMed CEO on how wearables, GLP-1s will impact sleep apnea device sales Leading CPAP device maker ResMed's CEO Mick Farrell sees 'two tidal waves' of innovation driving more people to the company's devices. By Mario Aguilar To aid addiction treatment, lawmakers tell DEA to back off buprenorphine enforcement Buprenorphine, also known as Suboxone, reduces opioid overdose deaths but is highly scrutinized by the DEA. A bill would make the agency ease up. By Lev Facher

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser